Clear All
11888 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
43598-0370-74 43598-0370 Pemetrexed disodium Pemetrexed disodium 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
67457-0486-99 67457-0486 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Mar 30, 2012 Apr 30, 2016 No Longer Used
70709-0153-70 70709-0153 Dasatinib PHYRAGO 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 22, 2025 In Use
67184-0532-02 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 21, 2022 In Use
00378-2245-77 00378-2245 imatinib Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 28, 2017 In Use
67457-0221-02 67457-0221 Methotrexate Methotrexate 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Jun 27, 2012 Nov 1, 2014 No Longer Used
16729-0522-05 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sep 8, 2022 Feb 28, 2025 No Longer Used
71335-2221-06 71335-2221 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 15, 2023 In Use
70709-0154-80 70709-0154 Dasatinib PHYRAGO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 22, 2025 In Use
60429-0265-01 60429-0265 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Oct 26, 2012 Dec 31, 2024 No Longer Used
42367-0121-25 42367-0121 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan 15, 2016 May 12, 2019 No Longer Used
71288-0166-91 71288-0166 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
71335-2221-02 71335-2221 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 15, 2023 In Use
16729-0048-53 16729-0048 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Mar 7, 2017 In Use
16729-0277-03 16729-0277 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Mar 7, 2014 In Use
73594-0101-01 73594-0101 Trilaciclib COSELA 300.0 mg/20mL Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Intravenous Aug 25, 2025 In Use
00338-0080-01 00338-0080 Doxorubicin Hydrochloride Liposome Doxorubicin Hydrochloride Liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug 15, 2019 In Use
52652-2001-06 52652-2001 Methotrexate Xatmep 2.5 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 13, 2018 In Use
00078-0916-61 00078-0916 Letrozole and ribociclib Kisqali Femara Co-pack 2.5 mg/1, 200.0 mg/1 Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6, Hormonal Oral May 4, 2017 Aug 31, 2026 In Use
00078-0923-61 00078-0923 letrozole and ribociclib Kisqali Femara Co-pack 2.5 mg/1, 200.0 mg/1 Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6, Hormonal Oral May 4, 2017 Aug 31, 2026 In Use
00078-0909-61 00078-0909 letrozole and ribociclib Kisqali Femara Co-pack 2.5 mg/1, 200.0 mg/1 Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6, Hormonal Oral May 4, 2017 Aug 31, 2026 In Use
50090-1600-03 50090-1600 ondansetron hydrochloride Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan 5, 2015 Aug 31, 2017 In Use
55513-0093-01 55513-0093 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sep 25, 2006 Feb 28, 2009 No Longer Used
69639-0102-01 69639-0102 Fosnetupitant and Palonosetron AKYNZEO 260.0 mg/1, 0.28 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Intravenous Apr 20, 2018 In Use
00093-7302-03 00093-7302 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 23, 2010 Nov 30, 2012 No Longer Used

Found 11888 results — Export these results